{ "cells": [ { "cell_type": "code", "execution_count": 1, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n", " from tqdm.autonotebook import tqdm, trange\n" ] } ], "source": [ "from sentence_transformers import SentenceTransformer, util\n", "import pandas as pd\n", "import re" ] }, { "cell_type": "code", "execution_count": 2, "metadata": {}, "outputs": [], "source": [ "# Target列を分割する関数\n", "def split_target(target):\n", " # 指定された区切り文字で分割\n", " split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n", " # 空白文字を除外してリストとして返す\n", " return [word.strip() for word in split_words if word.strip()]" ] }, { "cell_type": "code", "execution_count": 3, "metadata": {}, "outputs": [], "source": [ "basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241202Cancer.csv', index_col=0)\n", "basedf = basedf.dropna(subset=['試験等のフェーズ'])\n", "# Target列を分割してTargetWord列を追加\n", "basedf['TargetWord'] = basedf['Target'].apply(split_target)" ] }, { "cell_type": "code", "execution_count": 4, "metadata": {}, "outputs": [ { "data": { "application/vnd.jupyter.widget-view+json": { "model_id": "5ae79a392bff4b6284636dc3fae01e9e", "version_major": 2, "version_minor": 0 }, "text/plain": [ "modules.json: 0%| | 0.00/229 [00:00\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTarget研究・治験の目的試験等のフェーズ試験の種類無作為化盲検化...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
72jRCT2051240141NCT05580562NaN新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO...H3 K27M 変異を有する初発びまん性神経膠腫H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20...3NaN無作為化比較二重盲検...treatment purpose1. Able to understand the study procedures and...1. Primary spinal tumor.\\r\\n2. Diffuse intrins...No limitNo limitNaNNaNNaNParticipants will be randomized at baseline in...[H3 K27M 変異を有する初発, ん性神経膠腫]
103jRCT2051240121NCT06413706NaN放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ+テモゾロミドとテモゾ...悪性神経膠腫放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...2NaN無作為化比較非盲検...treatment purposeSubjects required to meet all the folloiwng cr...Patients who meets any of the following criter...No limit21age old notNaNNaNNaNDrug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...[悪性神経膠腫]
224jRCT2031240090NaNNaN再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...悪性神経膠腫再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl...3NaN無作為化比較非盲検...treatment purpose1) Histologically diagnosed as high grade glio...1) Have a history or merger of other malignanc...18age old over75age old underBothNaNglioblastoma, grade3/4 astrocytoma, grade3 oli...Group A: BPC Therapy\\r\\nDepending on the patie...[悪性神経膠腫]
473jRCT2051230069NaNNaN神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...1NaN単一群非盲検...treatment purpose<Cohort 1>\\r\\n All of the following items shal...<Common to Cohort 1 and Cohort 2>\\r\\n1) Active...18age old overNo limitBothNaNNaN<cohort1>\\r\\nLomustine 130 mg/m2 orally every ...[神経膠腫]
549jRCT2031230007NaNNaNBRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...低悪性度神経膠腫、膵癌BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A...2NaN単一群非盲検...treatment purposeInclusion criteria for both cohort A and B\\r\\n...1) Active double primary cancer (but not (1)-(...12age old overNo limitBothNaNBRAF fusion gene, BRAF rearrangement, low-grad...Binimetinib is administered 45 mg orally, twic...[低悪性度神経膠腫, 膵癌]
875jRCT2031210299NaNNaN再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...1NaN単一群非盲検...treatment purpose1.\\tEstimated life expectancy >= 3 months\\r\\n2...1.\\tPrior therapy with bevacizumab or other an...18age old overNo limitBothNaNNaNPatients will receive DSP-0390 orally once dai...[再発悪性神経膠腫]
981jRCT2031200153NaNNaNCellm-001による初発膠芽腫治療効果無作為比較対照試験膠芽腫脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...3NaN無作為化比較二重盲検...treatment purpose(1) 18 years old or older and 75 years old or ...(1) Systemic administration of corticosteroids...18age old over75age old underBothNaNNaNInject the investigational drug (Cellm-001 or ...[膠芽腫]
\n", "

7 rows × 39 columns

\n", "" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "72 jRCT2051240141 NCT05580562 NaN \n", "103 jRCT2051240121 NCT06413706 NaN \n", "224 jRCT2031240090 NaN NaN \n", "473 jRCT2051230069 NaN NaN \n", "549 jRCT2031230007 NaN NaN \n", "875 jRCT2031210299 NaN NaN \n", "981 jRCT2031200153 NaN NaN \n", "\n", " Title \\\n", "72 新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO... \n", "103 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ+テモゾロミドとテモゾ... \n", "224 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n", "473 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n", "549 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n", "875 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n", "981 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 \n", "\n", " Target \\\n", "72 H3 K27M 変異を有する初発びまん性神経膠腫 \n", "103 悪性神経膠腫 \n", "224 悪性神経膠腫 \n", "473 神経膠腫 \n", "549 低悪性度神経膠腫、膵癌 \n", "875 再発悪性神経膠腫 \n", "981 膠芽腫 \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 無作為化 \\\n", "72 H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20... 3 NaN 無作為化比較 \n", "103 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN 無作為化比較 \n", "224 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl... 3 NaN 無作為化比較 \n", "473 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 1 NaN 単一群 \n", "549 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A... 2 NaN 単一群 \n", "875 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN 単一群 \n", "981 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN 無作為化比較 \n", "\n", " 盲検化 ... purpose \\\n", "72 二重盲検 ... treatment purpose \n", "103 非盲検 ... treatment purpose \n", "224 非盲検 ... treatment purpose \n", "473 非盲検 ... treatment purpose \n", "549 非盲検 ... treatment purpose \n", "875 非盲検 ... treatment purpose \n", "981 二重盲検 ... treatment purpose \n", "\n", " Inclusion Criteria \\\n", "72 1. Able to understand the study procedures and... \n", "103 Subjects required to meet all the folloiwng cr... \n", "224 1) Histologically diagnosed as high grade glio... \n", "473 \\r\\n All of the following items shal... \n", "549 Inclusion criteria for both cohort A and B\\r\\n... \n", "875 1.\\tEstimated life expectancy >= 3 months\\r\\n2... \n", "981 (1) 18 years old or older and 75 years old or ... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "72 1. Primary spinal tumor.\\r\\n2. Diffuse intrins... No limit \n", "103 Patients who meets any of the following criter... No limit \n", "224 1) Have a history or merger of other malignanc... 18age old over \n", "473 \\r\\n1) Active... 18age old over \n", "549 1) Active double primary cancer (but not (1)-(... 12age old over \n", "875 1.\\tPrior therapy with bevacizumab or other an... 18age old over \n", "981 (1) Systemic administration of corticosteroids... 18age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "72 No limit NaN NaN \n", "103 21age old not NaN NaN \n", "224 75age old under Both NaN \n", "473 No limit Both NaN \n", "549 No limit Both NaN \n", "875 No limit Both NaN \n", "981 75age old under Both NaN \n", "\n", " Keyword \\\n", "72 NaN \n", "103 NaN \n", "224 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n", "473 NaN \n", "549 BRAF fusion gene, BRAF rearrangement, low-grad... \n", "875 NaN \n", "981 NaN \n", "\n", " Intervention(s) \\\n", "72 Participants will be randomized at baseline in... \n", "103 Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt... \n", "224 Group A: BPC Therapy\\r\\nDepending on the patie... \n", "473 \\r\\nLomustine 130 mg/m2 orally every ... \n", "549 Binimetinib is administered 45 mg orally, twic... \n", "875 Patients will receive DSP-0390 orally once dai... \n", "981 Inject the investigational drug (Cellm-001 or ... \n", "\n", " TargetWord \n", "72 [H3 K27M 変異を有する初発, ん性神経膠腫] \n", "103 [悪性神経膠腫] \n", "224 [悪性神経膠腫] \n", "473 [神経膠腫] \n", "549 [低悪性度神経膠腫, 膵癌] \n", "875 [再発悪性神経膠腫] \n", "981 [膠芽腫] \n", "\n", "[7 rows x 39 columns]" ] }, "execution_count": 56, "metadata": {}, "output_type": "execute_result" } ], "source": [ "# ターゲットリスト全体を処理\n", "matched_indices = []\n", "target_vecs_list = []\n", "cosine_scores_list = []\n", "for idx, target_words in enumerate(basedf['TargetWord']):\n", " # ターゲット内の各単語をベクトル化\n", " target_vecs = model.encode(target_words, convert_to_tensor=True)\n", " # コサイン類似度を計算\n", " cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n", " target_vecs_list.append(target_vecs)\n", " cosine_scores_list.append(cosine_scores)\n", " # 閾値を超えるか確認\n", " if (cosine_scores >= threshold).any(): # いずれかが閾値を超えている場合\n", " matched_indices.append(idx)\n", "\n", "# 抽出\n", "matched_df = basedf.iloc[matched_indices]\n", "matched_df" ] }, { "cell_type": "code", "execution_count": 57, "metadata": {}, "outputs": [], "source": [ "# 全データのターゲット列をベクトル化\n", "target_list = basedf['Target'].tolist()\n", "target_vecs = model.encode(target_list, convert_to_tensor=True)\n", "# コサイン類似度を計算\n", "cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()" ] }, { "cell_type": "code", "execution_count": 58, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTarget研究・治験の目的試験等のフェーズ試験の種類無作為化盲検化...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
103jRCT2051240121NCT06413706NaN放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ+テモゾロミドとテモゾ...悪性神経膠腫放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...2NaN無作為化比較非盲検...treatment purposeSubjects required to meet all the folloiwng cr...Patients who meets any of the following criter...No limit21age old notNaNNaNNaNDrug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...[悪性神経膠腫]
224jRCT2031240090NaNNaN再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...悪性神経膠腫再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl...3NaN無作為化比較非盲検...treatment purpose1) Histologically diagnosed as high grade glio...1) Have a history or merger of other malignanc...18age old over75age old underBothNaNglioblastoma, grade3/4 astrocytoma, grade3 oli...Group A: BPC Therapy\\r\\nDepending on the patie...[悪性神経膠腫]
473jRCT2051230069NaNNaN神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...1NaN単一群非盲検...treatment purpose<Cohort 1>\\r\\n All of the following items shal...<Common to Cohort 1 and Cohort 2>\\r\\n1) Active...18age old overNo limitBothNaNNaN<cohort1>\\r\\nLomustine 130 mg/m2 orally every ...[神経膠腫]
875jRCT2031210299NaNNaN再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...1NaN単一群非盲検...treatment purpose1.\\tEstimated life expectancy >= 3 months\\r\\n2...1.\\tPrior therapy with bevacizumab or other an...18age old overNo limitBothNaNNaNPatients will receive DSP-0390 orally once dai...[再発悪性神経膠腫]
981jRCT2031200153NaNNaNCellm-001による初発膠芽腫治療効果無作為比較対照試験膠芽腫脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...3NaN無作為化比較二重盲検...treatment purpose(1) 18 years old or older and 75 years old or ...(1) Systemic administration of corticosteroids...18age old over75age old underBothNaNNaNInject the investigational drug (Cellm-001 or ...[膠芽腫]
\n", "

5 rows × 39 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "103 jRCT2051240121 NCT06413706 NaN \n", "224 jRCT2031240090 NaN NaN \n", "473 jRCT2051230069 NaN NaN \n", "875 jRCT2031210299 NaN NaN \n", "981 jRCT2031200153 NaN NaN \n", "\n", " Title Target \\\n", "103 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ+テモゾロミドとテモゾ... 悪性神経膠腫 \n", "224 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... 悪性神経膠腫 \n", "473 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 神経膠腫 \n", "875 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 再発悪性神経膠腫 \n", "981 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 無作為化 \\\n", "103 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN 無作為化比較 \n", "224 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl... 3 NaN 無作為化比較 \n", "473 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 1 NaN 単一群 \n", "875 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN 単一群 \n", "981 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN 無作為化比較 \n", "\n", " 盲検化 ... purpose \\\n", "103 非盲検 ... treatment purpose \n", "224 非盲検 ... treatment purpose \n", "473 非盲検 ... treatment purpose \n", "875 非盲検 ... treatment purpose \n", "981 二重盲検 ... treatment purpose \n", "\n", " Inclusion Criteria \\\n", "103 Subjects required to meet all the folloiwng cr... \n", "224 1) Histologically diagnosed as high grade glio... \n", "473 \\r\\n All of the following items shal... \n", "875 1.\\tEstimated life expectancy >= 3 months\\r\\n2... \n", "981 (1) 18 years old or older and 75 years old or ... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "103 Patients who meets any of the following criter... No limit \n", "224 1) Have a history or merger of other malignanc... 18age old over \n", "473 \\r\\n1) Active... 18age old over \n", "875 1.\\tPrior therapy with bevacizumab or other an... 18age old over \n", "981 (1) Systemic administration of corticosteroids... 18age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "103 21age old not NaN NaN \n", "224 75age old under Both NaN \n", "473 No limit Both NaN \n", "875 No limit Both NaN \n", "981 75age old under Both NaN \n", "\n", " Keyword \\\n", "103 NaN \n", "224 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n", "473 NaN \n", "875 NaN \n", "981 NaN \n", "\n", " Intervention(s) TargetWord \n", "103 Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt... [悪性神経膠腫] \n", "224 Group A: BPC Therapy\\r\\nDepending on the patie... [悪性神経膠腫] \n", "473 \\r\\nLomustine 130 mg/m2 orally every ... [神経膠腫] \n", "875 Patients will receive DSP-0390 orally once dai... [再発悪性神経膠腫] \n", "981 Inject the investigational drug (Cellm-001 or ... [膠芽腫] \n", "\n", "[5 rows x 39 columns]" ] }, "execution_count": 58, "metadata": {}, "output_type": "execute_result" } ], "source": [ "matched_indices_d = (cosine_scores >= threshold).nonzero().tolist()\n", "# 入れ子リストをフラットなリストに変換\n", "flat_indices_d = [idx[0] for idx in matched_indices_d]\n", "\n", "# 抽出\n", "matched_df_d = basedf.iloc[flat_indices_d]\n", "matched_df_d\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] }, { "cell_type": "markdown", "metadata": {}, "source": [] }, { "cell_type": "markdown", "metadata": {}, "source": [ "\n", "\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [ "\n", "\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] }, { "cell_type": "markdown", "metadata": {}, "source": [ "\n" ] } ], "metadata": { "kernelspec": { "display_name": "gradio", "language": "python", "name": "python3" }, "language_info": { "codemirror_mode": { "name": "ipython", "version": 3 }, "file_extension": ".py", "mimetype": "text/x-python", "name": "python", "nbconvert_exporter": "python", "pygments_lexer": "ipython3", "version": "3.12.3" } }, "nbformat": 4, "nbformat_minor": 2 }